Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)

NCT00171301 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

233

Enrollment

INDUSTRY

Sponsor class

Conditions

Beta-thalassemia Major
Hemosiderosis
Iron Overload
Rare Anemia

Interventions

DRUG: Deferasirox

Sponsor

Novartis Pharmaceuticals